(Q39187442)

9 September 2017

title

Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy? (English)

1 reference

9 September 2017

1 reference

9

Gerardo Botti

1 reference

9 September 2017

8

Alessandro Morabito

1 reference

9 September 2017

Paolo Antonio Ascierto

2

object named as

Paolo Antonio Ascierto

1 reference

9 September 2017

1

Federica Zito Marino

1 reference

9 September 2017

Roberto Alfano

7

1 reference

ORCID Public Data File 2021

author name string

Giulio Rossi

3

1 reference

9 September 2017

Stefania Staibano

4

1 reference

9 September 2017

Marco Montella

5

1 reference

9 September 2017

Daniela Russo

6

1 reference

9 September 2017

Renato Franco

10

1 reference

9 September 2017

language of work or name

English

0 references

publication date

20 March 2017

1 reference

Expert Opinion on Biological Therapy

9 September 2017

published in

1 reference

9 September 2017

volume

17

1 reference

9 September 2017

issue

6

1 reference

9 September 2017

page(s)

735-746

1 reference

Tumor microenvironment: the role of the tumor stroma in cancer

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Prognostic and predictive impact of intra- and peritumoral immune infiltrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Cutaneous malignant melanoma in the Swedish organ transplantation cohort: A study of clinicopathological characteristics and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Tumor infiltrating lymphocytes (TIL) and prognosis in oral cavity squamous carcinoma: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Checkpoint blockade in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Classifying Cancers Based on T-cell Infiltration and PD-L1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Prognostic Role of Tumor-Infiltrating Lymphocytes in Lung Cancer: a Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Clinicopathological and prognostic significance of FOXP3+ tumor infiltrating lymphocytes in patients with breast cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Infiltrating lymphocytes and human papillomavirus-16--associated oropharyngeal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Lymphocytic infiltration and survival in rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Model predicting survival in stage I melanoma based on tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: implications for tumor biology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Stromal CD4/CD25 positive T-cells are a strong and independent prognostic factor in non-small cell lung cancer patients, especially with adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Immunological aspects of cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Systemic effects of local radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Immune checkpoint blockade: a common denominator approach to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

21 January 2018

The B7 family revisited

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Coordinated regulation of myeloid cells by tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Biomarkers on melanoma patient T cells associated with ipilimumab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

PD-1 blockade induces responses by inhibiting adaptive immune resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

B7-H1 expression in Wilms tumor: correlation with tumor biology and disease recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Radiotherapy combination opportunities leveraging immunity for the next oncology practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Combination of radiotherapy and immune checkpoint inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1309387

10.1080/14712598.2017.1309387

21 January 2018

Identifiers

DOI

1 reference

9 September 2017

1 reference